Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 7
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Depth of response in multiple myeloma: A pooled analysis of three PETHEMA/GEM clinical trials

  • Lahuerta, Juan José
  • Paiva, Bruno
  • Vidriales, Maria Belén
  • Cordón, Lourdes
  • Cedena, Maria-Teresa
  • Puig, Noemi
  • Martínez-López, Joaquín
  • Rosiñol, Laura
  • Gutiérrez, Norma Carmen
  • Martín-Ramos, María-Luisa
  • Oriol, Albert
  • Teruel, Ana-Isabel
  • Echeveste, María-Asunción
  • Paz, Raquel de
  • Arriba, Felipe de
  • Hernandez, Miguel T.
  • Palomera, Luis
  • Martínez, Rafael
  • Martín, Alejandro
  • Alegre, Adrián
  • Rubia, Javier de la
  • Orfao, Alberto
  • Mateos, Maria Victoria
  • Bladé, Joan
  • San Miguel, Jesús F.
On behalf of the GEM (Grupo Español de Mieloma)/PETHEMA (Programa para el Estudio de la Terapéutica en Hemopatías Malignas) Cooperative Study Group., [Purpose]: To perform a critical analysis on the impact of depth of response in newly diagnosed multiple myeloma (MM). [Patients and Methods]: Data were analyzed from 609 patients who were enrolled in the GEM (Grupo Español de Mieloma) 2000 and GEM2005MENOS65 studies for transplant-eligible MM and the GEM2010MAS65 clinical trial for elderly patients with MM who had minimal residual disease (MRD) assessments 9 months after study enrollment. Median follow-up of the series was 71 months. [Results]: Achievement of complete remission (CR) in the absence of MRD negativity was not associated with prolonged progression-free survival (PFS) and overall survival (OS) compared with near-CR or partial response (median PFS, 27, 27, and 29 months, respectively; median OS, 59, 64, and 65 months, respectively). MRD-negative status was strongly associated with prolonged PFS (median, 63 months; P < .001) and OS (median not reached; P < .001) overall and in subgroups defined by prior transplantation, disease stage, and cytogenetics, with prognostic superiority of MRD negativity versus CR particularly evident in patients with high-risk cytogenetics. Accordingly, Harrell C statistics showed higher discrimination for both PFS and OS in Cox models that included MRD (as opposed to CR) for response assessment. Superior MRD-negative rates after different induction regimens anticipated prolonged PFS. Among 34 MRD-negative patients with MM and a phenotypic pattern of bone marrow involvement similar to monoclonal gammopathy of undetermined significance at diagnosis, the probability of >operational cure> was high; median PFS was 12 years, and the 10-year OS rate was 94%. [Conclusion]: Our results demonstrate that MRD-negative status surpasses the prognostic value of CR achievement for PFS and OS across the disease spectrum, regardless of the type of treatment or patient risk group. MRD negativity should be considered as one of the most relevant end points for transplant-eligible and elderly fit patients with MM., Supported by the Centro de Investigación Biomédica en Red – Area de Oncologia - del Instituto de Salud Carlos III (CIBERONC; CB16/12/00369; CB16/12/00400; CB16/12/00233; CB16/12/00284), formerly named as Cooperative Research Thematic Network (Grants No. RD12/0036/0058, RD12/0036/0048, RD12/0036/0046, and RD12/0036/0061) of the Red de Cancer (Cancer Network of Excellence); Instituto de Salud Carlos III/Subdirección General de Investigación Sanitaria; funded in part by the European Regional Development Fund (FIS No. 98/1239, 00/10160, 01/0089, 02/0089, 02/0905, G03/136, PI051284, PI06033906/1354, PS09/01897/01370, PI12/01761, PI12/02311, PI13/01469, PI14/01867, G03/136); Sara Borrell (No. CD13/00340); Asociación Española Contra el Cáncer (No. GCB120981SAN); and Federación Española de Enfermedades Raras. Also supported internationally by the Black Swan Research Initiative of the International Myeloma Foundation and the European Research Council 2015 Starting Grant (MYELOMANEXT)., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Prognostic value of antigen expression in multiple myeloma: a PETHEMA/GEM study on 1265 patients enrolled in four consecutive clinical trials

  • Arana, Paula
  • Paiva, Bruno
  • Cedena, Maria-Teresa
  • Puig, Noemi
  • Cordón, Lourdes
  • Vidriales, Maria Belén
  • Gutiérrez, Norma Carmen
  • Chiodi, Francesca
  • Burgos, Leire
  • Anglada, Lucia-Lopez
  • Martínez-López, Joaquín
  • Hernandez, Miguel T.
  • Teruel, Ana-Isabel
  • Gironella, Mercedes
  • Echeveste, María-Asunción
  • Rosiñol, Laura
  • Martínez, Rafael
  • Oriol, Albert
  • Rubia, Javier de la
  • Orfao, Alberto
  • Bladé, Joan
  • Lahuerta, Juan José
  • Mateos, Maria Victoria
  • San Miguel, Jesús F.
Persistence of minimal residual disease (MRD) after treatment for myeloma predicts inferior outcomes, but within MRD-positive patients there is great heterogeneity with both early and very late relapses. Among different MRD techniques, flow cytometry provides additional information about antigen expression on tumor cells, which could potentially contribute to stratify MRD-positive patients. We investigated the prognostic value of those antigens required to monitor MRD in 1265 newly diagnosed patients enrolled in the GEM2000, GEM2005MENOS65, GEM2005MAS65 and GEM2010MAS65 protocols. Overall, CD19 pos, CD27 neg, CD38 lo, CD45 pos, CD81 pos, CD117 neg and CD138 lo expression predicted inferior outcomes. Through principal component analysis, we found that simultaneous CD38 low CD81 pos CD117 neg expression emerged as the most powerful combination with independent prognostic value for progression-free survival (HR:1.69; P=0.002). This unique phenotypic profile retained prognostic value among MRD-positive patients. We then used next-generation flow to determine antigen stability throughout the course of the disease, and found that the expression of antigens required to monitor MRD is mostly stable from diagnosis to MRD stages, except for CD81 whose expression progressively increased from baseline to chemoresistant tumor cells (14 vs 28%). Altogether, we showed that the phenotypic profile of tumor cells provides additional prognostic information, and could be used to further predict risk of relapse among MRD-positive patients., On behalf of the GEM (Grupo Español de Mieloma)/PETHEMA (Programa para el Estudio de la Terapéutica en Hemopatías Malignas) cooperative study group. This study was supported by the Centro de Investigación Biomédica en Red – Área de Oncología - del Instituto de Salud Carlos III (CIBERONC; CB16/12/00369; CB16/12/00400; CB16/12/00233; CB16/12/00284), formerly named as Cooperative Research Thematic Network (Grants No. RD12/0036/0058, RD12/0036/0048, RD12/0036/0046, and RD12/0036/0061) of the Red de Cancer (Cancer Network of Excellence); Instituto de Salud Carlos III/Subdirección General de Investigación Sanitaria; funded in part by the European Regional Development Fund (FIS No. 98/1239, 00/10160, 01/0089, 02/0089, 02/0905, G03/136, PI051284, PI06033906/1354, PS09/01897/01370, PI12/01761, PI12/ 02311, PI13/01469, PI14/01867, G03/136); Sara Borrell (No. CD13/00340); Asociación Española Contra el Cáncer (GCB120981SAN). This study was also supported internationally by the Black Swan Research Initiative of the International Myeloma Foundation, the Qatar National Research Fund (QNRF) Award No. 7-916-3-237, the AACR-Millennium Fellowship in Multiple Myeloma Research (15-40-38-PAIV), the Leukemia Research Foundation, and the European Research Council (ERC) 2015 Starting Grant (MYELOMANEXT)., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Transcriptional profiling of circulating tumor cells in multiple myeloma: a new model to understand disease dissemination

  • Garcés, Juan José
  • Burgos, Leire
  • Alignani, Diego
  • Calasanz, Mª Jose
  • Agirre, Xavier
  • Prósper, Felipe
  • Ríos, Rafael
  • Martínez-López, Joaquín
  • Palomera, Luis
  • Pérez-Montaña, Albert
  • Blanco, María Laura
  • Lasa, Marta
  • Maiso, Patricia
  • Flores-Montero, Juan
  • Sanoja-Flores, Luzalba
  • Orfao, Alberto
  • Hajek, Roman
  • San Miguel, Jesús F.
  • Paiva, Bruno
The reason why a few myeloma cells egress from the bone marrow (BM) into peripheral blood (PB) remains unknown. Here, we investigated molecular hallmarks of circulating tumor cells (CTCs) to identify the events leading to myeloma trafficking into the bloodstream. After using next-generation flow to isolate matched CTCs and BM tumor cells from 32 patients, we found high correlation in gene expression at single-cell and bulk levels (r ≥ 0.94, P = 10−16), with only 55 genes differentially expressed between CTCs and BM tumor cells. CTCs overexpressed genes involved in inflammation, hypoxia, or epithelial–mesenchymal transition, whereas genes related with proliferation were downregulated in CTCs. The cancer stem cell marker CD44 was overexpressed in CTCs, and its knockdown significantly reduced migration of MM cells towards SDF1-α and their adhesion to fibronectin. Approximately half (29/55) of genes differentially expressed in CTCs were prognostic in patients with newly-diagnosed myeloma (n = 553; CoMMpass). In a multivariate analysis including the R-ISS, overexpression of CENPF and LGALS1 was significantly associated with inferior survival. Altogether, these results help understanding the presence of CTCs in PB and suggest that hypoxic BM niches together with a pro-inflammatory microenvironment induce an arrest in proliferation, forcing tumor cells to circulate in PB and seek other BM niches to continue growing., This study was supported by the Centro de Investigación Biomédica en Red —Área de Oncología— del Instituto de Salud Carlos III (CIBERONC; CB16/12/00369, CB16/12/00489, and CB16/12/00400), Cancer Research UK, FCAECC and AIRC under the Accelerator Award Programme, Instituto de Salud Carlos III and Asociación Española Contra el Cáncer by ERA-NET TRANSCAN-2 Programme (AC17/00101), the Black Swan Research Initiative of the International Myeloma Foundation, the European Research Council (ERC) 2015 Starting Grant (MYELOMANEXT, 680200), the Czech Science Foundation through Project No. 19-25354Y, the European Regional Development Fund—Project ENOCH (No. CZ.02.1.01/0.0/0.0/16_019/0000868), and the Ministry of Health of the Czech Republic (15-29667A)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Circulating tumor cells for comprehensive and multiregional non-invasive genetic characterization of multiple myeloma

  • Garcés, Juan José
  • Bretones, Gabriel
  • Burgos, Leire
  • Valdes-Mas, Rafael
  • Puig, Noemi
  • Cedena, Maria-Teresa
  • Alignani, Diego
  • Rodríguez, Idoia
  • Álvarez Puente, Diana
  • García Álvarez, Miguel
  • Goicoechea, Ibai
  • Rodríguez, Sara
  • Calasanz, Mª Jose
  • Agirre, Xavier
  • Flores-Montero, Juan
  • Sanoja-Flores, Luzalba
  • Rodríguez-Otero, Paula
  • Ríos, Rafael
  • Martínez-López, Joaquín
  • Millacoy, Pamela
  • Palomera, Luis
  • Orbe, Rafael del
  • Pérez-Montaña, Albert
  • Omri, Halima El
  • Prósper, Felipe
  • Mateos, Maria Victoria
  • Rosiñol, Laura
  • Bladé, Joan
  • Lahuerta, Juan José
  • Orfao, Alberto
  • López-Otín, Carlos
  • Miguel, Jesus F. San
  • Paiva, Bruno
Multiple myeloma (MM) patients undergo repetitive bone marrow (BM) aspirates for genetic characterization. Circulating tumor cells (CTCs) are detectable in peripheral blood (PB) of virtually all MM cases and are prognostic, but their applicability for noninvasive screening has been poorly investigated. Here, we used next-generation flow (NGF) cytometry to isolate matched CTCs and BM tumor cells from 53 patients and compared their genetic profile. In eight cases, tumor cells from extramedullary (EM) plasmacytomas were also sorted and whole-exome sequencing was performed in the three spatially distributed tumor samples. CTCs were detectable by NGF in the PB of all patients with MM. Based on the cancer cell fraction of clonal and subclonal mutations, we found that ~22% of CTCs egressed from a BM (or EM) site distant from the matched BM aspirate. Concordance between BM tumor cells and CTCs was high for chromosome arm-level copy number alterations (≥95%) though not for translocations (39%). All high-risk genetic abnormalities except one t(4;14) were detected in CTCs whenever present in BM tumor cells. Noteworthy, ≥82% mutations present in BM and EM clones were detectable in CTCs. Altogether, these results support CTCs for noninvasive risk-stratification of MM patients based on their numbers and genetic profile., This study was supported by the Centro de Investigación Biomédica en Red—Área de Oncología—del Instituto de Salud Carlos III (CIBERONC; CB16/12/00236, CB16/12/00369, CB16/12/00489, and CB16/12/00400); by Cancer Research UK [C355/A26819] and FC AECC and AIRC under the Accelerator Award Program; by the Instituto de Salud Carlos III, FCAECC and co-financed by FEDER (ERANET-TRANSCAN-2 iMMunocell AC17/00101); the Spanish Ministry of Science and Innovation and co-financed by FSE (Torres Quevedo fellowship, PTQ-16-08623); the Black Swan Research Initiative of the International Myeloma Foundation; European Research Council (ERC) under the European Commission’s H2020 Framework Programme (MYELOMANEXT, 680200); the Qatar National Research Fund (QNRF) Award No. 7-916-3-237; the AACR-Millennium Fellowship in Multiple Myeloma Research (15-40-38-PAIV); the Leukemia Research Foundation; and the Multiple Myeloma Research Foundation (MMRF) under the 2019 Research Fellowship Award.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Reference Values to Assess Hemodilution and Warn of Potential False-Negative Minimal Residual Disease Results in Myeloma

  • Puig, Noemi
  • Flores-Montero, Juan
  • Burgos, Leire
  • Cedena, Maria-Teresa
  • Cordón, Lourdes
  • Pérez, José J.
  • Sanoja-Flores, Luzalba
  • Manrique, Irene
  • Rodríguez-Otero, Paula
  • Rosiñol, Laura
  • Martínez-López, Joaquín
  • Mateos, Maria Victoria
  • Lahuerta, Juan José
  • Bladé, Joan
  • San Miguel, Jesús F.
  • Orfao, Alberto
  • Paiva, Bruno
This article belongs to the Special Issue Advances in Multiple Myeloma Research and Treatment., [Simple Summary] Although the majority of patients with myeloma who achieve undetectable minimal residual disease show prolonged survival, some of them relapse shortly afterwards. False-negative results due to hemodiluted bone marrow samples could explain this inconsistency, but there is no guidance on how to evaluate them. We analyzed three cell populations normally absent in peripheral blood in 1404 aspirates obtained in numerous disease settings and in 85 healthy adults. Pairwise comparisons according to age and treatment showed significant variability, thus suggesting that hemodilution should be preferably evaluated with references obtained after receiving identical regimens. Leveraging the minimal residual disease results from 118 patients, we showed that a comparison with age-matched healthy adults could also inform on potential hemodilution. Our study supports the routine assessment of bone marrow cellularity to evaluate hemodilution, using as reference values either treatment-specific or from healthy adults if the former are unavailable., [Abstract] Background: Whereas, in most patients with multiple myeloma (MM), achieving undetectable MRD anticipates a favorable outcome, some others relapse shortly afterwards. Although one obvious explanation for this inconsistency is the use of nonrepresentative marrow samples due to hemodilution, there is no guidance on how to evaluate this issue. Methods: Since B-cell precursors, mast cells and nucleated red blood cells are normally absent in peripheral blood, we analyzed them in 1404 bone marrow (BM) aspirates obtained in numerous disease settings and in 85 healthy adults (HA). Results: First, we confirmed the systematic detection of the three populations in HA, as well as the nonreduced numbers with aging. Pairwise comparisons between HA and MM patients grouped according to age and treatment showed significant variability, suggesting that hemodilution should be preferably evaluated with references obtained from patients treated with identical regimens. Leveraging the MRD results from 118 patients, we showed that a comparison with HA of similar age could also inform on potential hemodilution. Conclusions: Our study supports the routine assessment of BM cellularity to evaluate hemodilution, since reduced BM-specific cell types as compared to reference values (either treatment-specific or from HA if the former are unavailable) could indicate hemodilution and a false-negative MRD result., This study was supported by grants from the Centro de Investigación Biomédica en Red—Área de Oncología—del Instituto de Salud Carlos III (CIBERONC; CB16/12/00369, CB16/12/00400, CB16/12/00233 and CB16/12/00284); Instituto de Salud Carlos III/Subdirección General de Investigación Sanitaria and co-financed by FEDER funds (FIS No. PI15/01956, PI15/02049, PI15/02062, PI18/01709, PI18/01673 and PI19/01451); the Cancer Research UK (C355/A26819), FCAECC and AIRC under the Accelerator Award Programme (EDITOR); the Black Swan Research Initiative of the International Myeloma Foundation and the European Research Council (ERC) 2015 Starting Grant (Contract 680200 MYELOMANEXT). This study was supported by the Riney Family Multiple Myeloma Research Program Fund.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma

  • Paiva, B.
  • Puig, N.
  • Cedena, M.T.
  • Rosiñol, L.
  • Cordón, L.
  • Vidriales, M.B.
  • Burgos, L.
  • Flores-Montero, J.
  • Sanoja-Flores, L.
  • Lopez-Anglada, L.
  • Maldonado, R.
  • de la Cruz, J.
  • Gutierrez, N.C.
  • Calasanz, M.J.
  • Martin-Ramos, M.L.
  • Garcia-Sanz, R.
  • Martinez-Lopez, J.
  • Oriol, A.
  • Blanchard, M.J.
  • Rios, R.
  • Martin, J.
  • Martinez-Martinez, R.
  • Sureda, A.
  • Hernandez, M.T.
  • de la Rubia, J.
  • Krsnik, I.
  • Moraleda, J.M.
  • Palomera, L.
  • Bargay, J.
  • Van Dongen, J.J.M.
  • Orfao, A.
  • Mateos, M.V.
  • Blade, J.
  • San-Miguel, J.F.
  • Lahuerta, J.J.
PURPOSE: Assessing measurable residual disease (MRD) has become standard with many tumors, but the clinical meaning of MRD in multiple myeloma (MM) remains uncertain, particularly when assessed by next-generation flow (NGF) cytometry. Thus, we aimed to determine the applicability and sensitivity of the flow MRD-negative criterion defined by the International Myeloma Working Group (IMWG). PATIENTS AND METHODS: In the PETHEMA/GEM2012MENOS65 trial, 458 patients with newly diagnosed MM had longitudinal assessment of MRD after six induction cycles with bortezomib, lenalidomide, and dexamethasone (VRD), autologous transplantation, and two consolidation courses with VRD. MRD was assessed in 1, 100 bone marrow samples from 397 patients; the 61 patients without MRD data discontinued treatment during induction and were considered MRD positive for intent-to-treat analysis. The median limit of detection achieved by NGF was 2.9 × 10-6. Patients received maintenance (lenalidomide ± ixazomib) according to the companion PETHEMA/GEM2014MAIN trial. RESULTS: Overall, 205 (45%) of 458 patients had undetectable MRD after consolidation, and only 14 of them (7%) have experienced progression thus far; seven of these 14 displayed extraosseous plasmacytomas at diagnosis and/or relapse. Using time-dependent analysis, patients with undetectable MRD had an 82% reduction in the risk of progression or death (hazard ratio, 0.18; 95% CI, 0.11 to 0.30; P < .001) and an 88% reduction in the risk of death (hazard ratio, 0.12; 95% CI, 0.05 to 0.29; P < .001). Timing of undetectable MRD (after induction v intensification) had no impact on patient survival. Attaining undetectable MRD overcame poor prognostic features at diagnosis, including high-risk cytogenetics. By contrast, patients with Revised International Staging System III status and positive MRD had dismal progression-free and overall survivals (median, 14 and 17 months, respectively). Maintenance increased the rate of undetectable MRD by 17%. CONCLUSION: The IMWG flow MRD-negative response criterion is highly applicable and sensitive to evaluate treatment efficacy in MM.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistance

  • Botta, Cirino
  • Perez, Cristina|||0000-0003-3586-2666
  • Larrayoz, Marta|||0000-0001-6097-8244
  • Puig, Noemí|||0000-0001-7535-3861
  • Cedena, María Teresa|||0000-0001-5851-3720
  • Termini, Rosalinda
  • Goicoechea, Ibai|||0000-0002-5329-2225
  • Rodriguez, Sara|||0000-0001-6509-0447
  • Zabaleta, Aintzane|||0000-0003-3474-3040
  • Lopez, Aitziber
  • Sarvide, Sarai
  • Blanco Fernández, Laura|||0000-0002-1859-0884
  • Papetti, Daniele Marco|||0000-0002-3574-6027
  • Nobile, M.S.
  • Besozzi, Daniela
  • Gentile, Massimo
  • Correale, Pierpaolo
  • Siragusa, Sergio
  • Oriol, Albert|||0000-0001-6804-2221
  • González Garcia, Maria Esther|||0000-0002-4238-0377
  • Sureda, Anna|||0000-0002-1238-6970
  • De Arriba, Felipe|||0000-0002-4451-1318
  • Ríos-Tamayo, Rafael|||0000-0001-8193-1402
  • Moraleda, José María|||0000-0001-9080-1466
  • Gironella, Mercedes|||0000-0002-8106-8909
  • Hernández, Miguel Teodoro|||0000-0002-6576-7881
  • Bargay, Joan|||0000-0002-6739-3916
  • Palomera, Luís
  • Pérez-Montaña, Albert
  • Goldschmidt, Hartmut|||0000-0003-0961-0035
  • Avet-Loiseau, Hervé
  • Roccaro, Aldo|||0000-0002-1872-5128
  • Orfao, Alberto|||0000-0002-0007-7230
  • Martinez-Lopez, Joaquín
  • Rosiñol, Laura|||0000-0002-2534-9239
  • Lahuerta, J. J.|||0000-0002-3393-9570
  • Bladé Creixenti, Juan|||0000-0002-4563-3405
  • Mateos, M. V.|||0000-0003-2390-1218
  • San Miguel, Jesús|||0000-0002-9183-4857
  • Martinez Climent, Juan-José|||0000-0002-7938-3950
  • Paiva, Bruno|||0000-0003-1977-3815
Tumor recognition by T cells is essential for antitumor immunity. A comprehensive characterization of T cell diversity may be key to understanding the success of immunomodulatory drugs and failure of PD-1 blockade in tumors such as multiple myeloma (MM). Here, we use single-cell RNA and T cell receptor sequencing to characterize bone marrow T cells from healthy adults (n = 4) and patients with precursor (n = 8) and full-blown MM (n = 10). Large T cell clones from patients with MM expressed multiple immune checkpoints, suggesting a potentially dysfunctional phenotype. Dual targeting of PD-1 + LAG3 or PD-1 + TIGIT partially restored their function in mice with MM. We identify phenotypic hallmarks of large intratumoral T cell clones, and demonstrate that the CD27 and CD27 T cell ratio, measured by flow cytometry, may serve as a surrogate of clonal T cell expansions and an independent prognostic factor in 543 patients with MM treated with lenalidomide-based treatment combinations.